BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2018, which is the Company’s first quarter of fiscal year 2019 (“1Q19").

The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1 hour and a duration of effect up to 13 hours after dosing

Physicians can earn degrees to practice medicine in the U.S. and the European Union

Trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD

Morneau Shepell’s clients recognized by Benefits Canada as leaders in employee benefits

Indiana and Pennsylvania osteopathic associations tap ISMIE as endorsed medical liability carrier

Millions of Customers Will Be Able to Sign Up for Online Education and Rewards through the DarioHealth Blood Glucose Monitoring System and Smartphone Application. [12-November-2018] CAESAREA, Israel , Nov. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it h

Single dose of NGM313 resulted in statistically significant reductions in liver fat content and multiple metabolic parameters of NASH and Type 2 diabetes

Astellas today announced that Eloiza Domingo-Snyder has been appointed to executive director of Diversity and Inclusion, Astellas US.

The LexisNexis® Risk Solutions healthcare business has identified the breast cancer treatment facilities in the U.S. with the highest patient volumes, based on its analysis of annual patient volume data ending in June 2018.